Paul Hamberg

4.1k total citations
118 papers, 2.1k citations indexed

About

Paul Hamberg is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Paul Hamberg has authored 118 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pulmonary and Respiratory Medicine, 61 papers in Oncology and 34 papers in Cancer Research. Recurrent topics in Paul Hamberg's work include Prostate Cancer Treatment and Research (49 papers), Cancer Genomics and Diagnostics (21 papers) and Renal cell carcinoma treatment (19 papers). Paul Hamberg is often cited by papers focused on Prostate Cancer Treatment and Research (49 papers), Cancer Genomics and Diagnostics (21 papers) and Renal cell carcinoma treatment (19 papers). Paul Hamberg collaborates with scholars based in Netherlands, United States and Belgium. Paul Hamberg's co-authors include Stefan Sleijfer, Jaap Verweij, Ronald de Wit, Ron H.J. Mathijssen, John W.M. Martens, Jaco Kraan, Anieta M. Sieuwerts, Martijn P. Lolkema, Wendy Onstenk and Luc Dirix and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Paul Hamberg

111 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Hamberg Netherlands	26	1.0k	927	633	624	317	118	2.1k
G. Deplanque France	23	812 0.8×	1.3k 1.4×	633 1.0×	542 0.9×	221 0.7×	77	2.3k
Jean‐Christophe Eymard France	15	987 1.0×	645 0.7×	512 0.8×	379 0.6×	213 0.7×	47	1.5k
David Lorente Spain	28	1.8k 1.8×	1.2k 1.3×	594 0.9×	1.1k 1.7×	653 2.1×	100	2.9k
Tomomi Kamba Japan	27	1.2k 1.1×	1.0k 1.1×	1.3k 2.1×	635 1.0×	262 0.8×	152	3.3k
Amna Ibrahim United States	26	1.1k 1.0×	1.7k 1.8×	744 1.2×	457 0.7×	615 1.9×	58	2.9k
Jackie Walling United States	16	878 0.8×	1.0k 1.1×	671 1.1×	252 0.4×	81 0.3×	45	1.9k
Julie N. Graff United States	25	2.3k 2.2×	1.2k 1.3×	664 1.0×	769 1.2×	638 2.0×	104	3.2k
L. Rhoda Molife United Kingdom	25	1.5k 1.5×	1.3k 1.4×	1.3k 2.1×	680 1.1×	229 0.7×	73	3.0k
Russell Z. Szmulewitz United States	25	2.0k 2.0×	888 1.0×	829 1.3×	756 1.2×	554 1.7×	121	2.9k

Countries citing papers authored by Paul Hamberg

Since Specialization

Citations

This map shows the geographic impact of Paul Hamberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Hamberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Hamberg more than expected).

Fields of papers citing papers by Paul Hamberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Hamberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Hamberg. The network helps show where Paul Hamberg may publish in the future.

Co-authorship network of co-authors of Paul Hamberg

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Hamberg. A scholar is included among the top collaborators of Paul Hamberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Hamberg. Paul Hamberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stevens, Michiel, John W.M. Martens, Jaco Kraan, et al.. (2025). PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients. Cancer Research Communications. 5(8). 1359–1371.

Robbrecht, Debbie, John W.M. Martens, Maureen J.B. Aarts, et al.. (2025). Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis. European Urology Oncology. 9(1). 7–11. 1 indexed citations

Zondervan, Patricia, Rob Kessels, Johannes Berkhof, et al.. (2024). PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor–based First-line Therapy in Metastatic Renal Cell Carcinoma Patients. European Urology Open Science. 70. 28–35. 1 indexed citations

Zande, Kim van der, Paul Hamberg, Annegien Broeks, et al.. (2024). Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy. Clinical Genitourinary Cancer. 22(2). 445–453.e1. 2 indexed citations

Robbrecht, Debbie, Alberto Gil-Jimenez, Hayri E. Balcıoğlu, et al.. (2024). Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer. Nature Communications. 15(1). 1349–1349. 6 indexed citations

Mostert, Bianca, Jaco Kraan, Vanja de Weerd, et al.. (2023). mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer. Molecular Oncology. 17(9). 1898–1907. 5 indexed citations

Tolmeijer, Sofie H., Takayuki Sumiyoshi, Edmond M. Kwan, et al.. (2023). Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(15). 2835–2844. 26 indexed citations

Weerd, Vanja de, Jaco Kraan, John W.M. Martens, et al.. (2023). Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer. JCO Precision Oncology. 7(7). e2300156–e2300156. 1 indexed citations

Somford, Diederik M., Paul Hamberg, Jolien Tol, et al.. (2023). The effect of a reduced dose of enzalutamide on fatigue and cognition.. Journal of Clinical Oncology. 41(16_suppl). 5051–5051. 1 indexed citations

10.

Robbrecht, Debbie, Mandy van Brakel, Joost L. Boormans, et al.. (2022). A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer. Cancer Immunology Immunotherapy. 72(3). 759–767. 9 indexed citations

11.

Dessel, Lisanne F. van, Jaco Kraan, Rui P. Neves, et al.. (2021). Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. European Journal of Cancer. 150. 179–189. 55 indexed citations

12.

Procopio, Giuseppe, Paul Hamberg, Pierre Bigot, et al.. (2020). 730P Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe. Annals of Oncology. 31. S571–S571. 1 indexed citations

13.

Hussaarts, Koen G. A. M., Esther Oomen‐de Hoop, Peter de Bruijn, et al.. (2019). Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study. British Journal of Clinical Pharmacology. 85(5). 986–992. 8 indexed citations

14.

Eijck, Casper H.J. van, et al.. (2018). “Duodenal Adenocarcinoma Giving Rise to Rectal Metastasis” a Rare Disease with an Extremely Rare Metastatic Pattern. Journal of Gastrointestinal Cancer. 50(3). 586–588. 1 indexed citations

15.

Velden, Daphne van der, Louisa R. Hoes, Hanneke van der Wijngaart, et al.. (2017). Expanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP). Annals of Oncology. 28. v649–v649.

16.

Nieuweboer, Annemieke J.M., Anne‐Joy M. de Graan, Paul Hamberg, et al.. (2016). Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study. Clinical Cancer Research. 23(7). 1679–1683. 12 indexed citations

17.

Coenen, J.L., Peter van den Berg, Inge M. van Oort, et al.. (2013). A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients. European Journal of Cancer. 49. 4 indexed citations

18.

Hamberg, Paul, Margaret M. Woo, Lin‐Chi Chen, et al.. (2011). Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemotherapy and Pharmacology. 68(3). 805–813. 42 indexed citations

19.

Baselga, José, Andrés Cervantes, Erika Martinelli, et al.. (2010). Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research. 16(19). 4876–4883. 95 indexed citations

20.

Hamberg, Paul, Neeltje Steeghs, Walter J. Loos, et al.. (2010). Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. British Journal of Cancer. 102(12). 1699–1706. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact